Oramed Executives Flip the Switch: CFO Avraham’s First RSU Grant Signals Bullish Future, Amid Mixed Insider Trades and Rising Stock Price

Insider Buying Signals a New Phase for Oramed

A recent Form 4 filing from Chief Financial Officer Gabay Avraham shows the company’s first purchase of restricted stock units (RSUs) in March 2026. 95,889 shares were awarded to Avraham at no cost, with vesting scheduled to begin April 1, 2026 and complete over eight quarters. The transaction raises Avraham’s post‑deal equity stake to 745,145 shares—an increase of roughly 22 % from the 649,256 shares held after the January 2026 buy/sell round. The price paid was $0, reflecting the typical grant‑style transaction for RSUs, but the grant itself signals management’s confidence in Oramed’s future upside.

Implications for Investors and Corporate Outlook

The timing and size of the RSU grant align with a broader pattern of insider activity. In the same month, COO & CBO Hexter Joshua made a sizable 95,889‑share purchase, and President & CEO Kidron Nadav recently sold 100,000 shares, netting a more than $3 million trade that left his holdings at 3,255,238 shares. The contrast between selling and buying activity suggests a strategic shift toward a longer‑term horizon. For investors, the RSU grant can be read as a bullish sign that management expects the stock to appreciate above its current $3.57 level, especially given Oramed’s strong quarterly momentum—52‑week high of $3.76 and a 50‑plus percent year‑to‑date gain.

A Profile of Gabay Avraham

Avraham’s insider history is characterized by a pattern of short‑term trading and a recent pivot toward equity compensation. In January 2026, he sold 19,000 performance‑stock units and bought an equivalent number of common shares, moving from 0 shares to 649,256 shares post‑transaction. The new RSU grant in March 2026 represents his first equity‑based award, indicating an intention to stay invested over the medium term. His trading volume remains modest compared to other executives—Hexter Joshua and Kidron Nadav have each completed multi‑hundred‑thousand‑share deals—yet the consistency of his activity suggests a disciplined approach to ownership.

What This Means for Oramed’s Future

With a market cap of just over $136 million and a price‑to‑earnings ratio of 3.54, Oramed sits on the fringe of the high‑growth pharmaceutical niche. The recent insider purchases, coupled with a 11.56 % monthly rise, suggest that executives believe the company’s oral‑insulin platform is on the cusp of broader commercial traction. Investors should watch for the first quarterly earnings report post‑grant, which will test whether the internal confidence translates into shareholder value. In the meantime, the modest but positive social‑media sentiment (+4) and below‑average buzz (10.88 %) imply that the market is still cautiously evaluating Oramed’s prospects.